Hard to Treat Diseases, Inc. (HTDS) CEO Audio Address Business Expectations for 2010

SHENZEN, China, May 24 /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS; http://www.htdsmedical.com) and Shenzhen Mellow Hope (www.mellowhope.com) is providing the following update to its shareholders and followers regarding business expectations for 2010

Mr.Terry Yuan CEO of HTDS has met with its IR firm Mina Mar Group here in China to address many concerns that shareholders have expressed. It was decided that the best way to address these concerns was to hear (audio recording) directly from the top brass. The company is pleased to provide raw, uncut, non scripted address by Mr Terry Yuan CEO of HTDS. The audio can be listened at www.minamargroup.com/htds The company reminds the audio listeners that English is a second language for Mr.Yuan and that he made the address based on FAQ questions posed by HTDS shareholders.

Here are some snippets from the audio recording. The company expects strong revenue increases in the upcoming Quarters. The company management developments on the global vaccine market (listed below), Mellow Hope expects to top the 2009 profits and further expand on the global vaccine market in 2010 and 2011. The company expects the income from MEVAC-ACYW (Meningococcal Polysaccharide Vaccine) in Pakistan and Indonesia to generate $2 million USD in 2010.

Regarding Mellow Hope's MEVAC-A vaccine, the company expects the existing market in India to increase at the rate of 20-40%. In this light, the company expects to increase its MEVAC-A sales in India by 100%. Besides India, the company received Clinical Trial Permit for the MEVAC-A vaccine in Russian Federation, and expects to obtain registration by the end of 2010, opening a large market for Mellow Hope.

Mellow Hope expects to finalize the approval of its Nutriprotein Product (Cerebroprotein Hydrolysate for Injection) in India in Jun/July 2010. The company will start marketing its Nutriprotein product immediately. Mellow Hope believes the company is the only one marketing this type of product in India, with a potential to generate $10 million USD in sales (the company expects to sell 2-3 million doses annually - press release March 1, 2010).

Besides these developments, the company continues to cooperate with health ministries in Asia, Europe and Latin America to gain approval for several other vaccines in 2010 and in 2011.

With all the current and planed developments, Mellow Hope management is confident that the shareholders will see stronger results in 2010 and in 2011, as the company will gain even larger market share on the global vaccine market. In other news and events,the company has filed all documents with FINRA for the HIRU shares distribution and expects to hear back from FINRA shortly. The company has also recently started subscribing to Pink Sheets filing service and will shortly update the Adequate Disclosure documents with a legal opinion from a USA legal counsel in aid of upgrading its Pink Sheets ranking.

The company reminds its shareholders and followers to monitor PinkSheets.com Filing section and also our IR company web site section "PRESS RELEASES AND FILINGS" TAB http://www.minamargroup.net/ for non newsworthy corporate updates.

For any matters relating to retail investor queries or to send the company or its IR a message please click on the "INVESTOR SUPPORT" TAB, or the direct link http://www.minamargroup.net/helpdesk. In this regard, Mina Mar Group works diligently to answer and address all the pressing issues regarding its clients to the shareholders' satisfaction. MMG is in constant contact with the companies, addressing, obtaining and processing all inquiries. MMG is often one of the advisors or IR companies utilized by the issuer. Depending on the location of the issuer and management's availability, it may take up to several days to address any pressing issues. In a normal course of business and a pending transaction, the issuer may opt to remain silent in order not to lose advantage to a competitor. MMG is mindful that sometimes shareholders want answers immediately, which for the above reasons cannot be fulfilled on a timely basis.

Don't be a victim. Report a stock basher to authorities. The company is mindful that short sellers, the company's competitors and stock bashers stalk small cap Pink Sheets listed companies with hidden agendas. Visit http://www.stockbasher.com/ and find out what criminal and civil actions the US authorities are taking against web sites like investorshub.com and other posters, and the remedies available to you as an individual investor. MMG encourages the readers to visit this investorshub.com blog and similar "investors" web sites with an open mind. Discover for yourself why and how USA based small businesses and the backbone of the economy suffer. Stay informed and do not allow entrepreneurs' dreams, innovations, and their access to capital to be thwarted as "scalpers" and day traders vigorously day in and day out try to exploit and extinguish US innovation and progress for quick profits.

Filings for this event are currently being reviewed and will be filed with Pink Sheets and Client Support section in due course. To be included in company's email database for press releases, industry updates, and non-weekly activity in the company that may or may not be news released, please subscribe or opt in mailer at http://www.minamargroup.com/updates.

Safe Harbor Statement

Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases, Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases, Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For any investor relations matters, please contact www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, www.minamargroup.net (IR); For (M&A) and Corporate Matters, www.minamargroup.com

SOURCE Hard to Treat Diseases